The dualistic model of endometrial cancer: The challenge of classifying grade 3 endometrioid carcinoma

Gynecologic Oncology

Volumn 127, Issue 1, 2012, Pages 262-263

  Zannoni, Gian Franco ^a   Scambia, Giovanni ^a   Gallo, Daniela ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR; KI 67 ANTIGEN; PROTEIN P53;

CANCER CLASSIFICATION; CANCER INVASION; CANCER SURVIVAL; CLEAR CELL CARCINOMA; ENDOMETRIOID CARCINOMA; IMMUNOHISTOCHEMISTRY; LETTER; PRIORITY JOURNAL;

CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS;

EID: 84865687920     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.09.036     Document Type: Letter

References (6)

1. J.L. Hecht, and G.L. Mutter Molecular and pathologic aspects of endometrial carcinogenesis J Clin Oncol 24 2006 4783 4791
2. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote Endometrial cancer Lancet 366 2005 491 505 Review.
3. B.A. Clarke, and C.B. Gilks Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type J Clin Pathol 63 2010 410 415
4. M.A. Voss, R. Ganesan, L. Ludeman, K. McCarthy, R. Gornall, and G. Schaller Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-A clinical and pathological evaluation Gynecol Oncol. 2011 Aug 22 [Epub ahead of print].
5. G.F. Zannoni, V.G. Vellone, V. Arena, M.G. Prisco, G. Scambia, and A. Carbone Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study Virchows Arch 457 2010 27 34
6. M. Reid-Nicholson, P. Iyengar, A.J. Hummer, I. Linkov, M. Asher, and R.A. Soslow Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis Mod Pathol 19 2006 1091 1100